Vivalis
Vivalis SA was a French biotech company focused on vaccine development that ceased independent operations on May 28, 2013, when it merged with Austria's Intercell AG to form Valneva SE.
- Company typePrivate
- Founded1999
- HeadquartersSaint-herblain, France
- Headcount101–250
- GTM typeB2B
- OfferingHardware or Manufacturing
Vivalis firmographics
Firmographics- Name
- Vivalis
- Legal name
- Vivalis SA
- Website
- https://vivalis.com
- Company type
- Private
- Founded year
- 1999
- Operating status
- Acquired
- Headcount range
- 101–250 employees
- Short description
- Vivalis SA was a French biotech company focused on vaccine development that ceased independent operations on May 28, 2013, when it merged with Austria's Intercell AG to form Valneva SE.
- Ownership category
- akta.pro rank
Vivalis industry classification
Industry- Product category
- Vaccines
- NAICS
- Pharmaceutical Preparation Manufacturing (325412)
- SIC
- Pharmaceutical Preparations (2834)
- akta.pro primary industry
- Vaccine Manufacturing & Fill-Finish (HLAIAEAJ)
Keywords
Where Vivalis is headquartered
LocationHeadquarters
- HQ city
- Saint-herblain
- HQ country
- France
- HQ region
- Europe
Markets served
Vivalis business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations
Vivalis product offering
Product offeringCore offering
Vivalis SA was a French biotechnology company operating in the pharmaceutical vaccines sector. The company merged with Intercell AG on May 28, 2013 to form Valneva SE, and its original website now redirects to the successor entity at www.valneva.com.
Differentiator
Problem solved
Functional benefit
Vivalis technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Vivalis partnerships and signals
Strategic signalPartnerships
One partnership is on record.
- Intercell AGcoreOn May 28, 2013, Vivalis SA merged with Intercell AG to create Valneva SE. This was a full merger of equals combining two pharmaceutical/biotechnology companies. The merged entity operates under the name Valneva SE.
Vivalis competitors and assessment
Company assessmentDirect peers
- Emergent BioSolutions: Mid-cap vaccine and biologics manufacturer with a portfolio of travel/contract-manufactured vaccines and therapeutics; comparable in scale and product mix to a combined Vivalis-Intercell entity.
- Bavarian Nordic: Specialty vaccine developer of comparable European-mid-size scale focused on infectious disease and oncology vaccines; the most direct peer to Vivalis's vaccine-manufacturing focus at similar headcount and stage.
- Novavax: Vaccine developer focused on recombinant nanoparticle vaccines; overlapping target markets (infectious disease) and similar commercialization-stage profile to Vivalis's successor Valneva SE.
Emerging players
- BioNTech: mRNA-platform vaccine and immuno-oncology developer; comparable as a European-headquartered emerging biotech that scaled via partnerships into global vaccine markets.
- Moderna: mRNA-based vaccine and therapeutics developer that has scaled rapidly and competes in infectious disease; relevant as a comparable emerging biotech with platform-vaccine ambitions.
- Dynavax Technologies: Smaller commercial-stage vaccine company with adjuvanted vaccine platforms; relevant as a peer in the niche vaccine space where Vivalis competed.
Broad incumbents
- Sanofi Pasteur: Global vaccine division of Sanofi and one of the largest vaccine manufacturers; serves as the dominant broad incumbent against which Vivalis and its successor Valneva compete.
- Merck Vaccines (MSD): Large pharmaceutical incumbent with a substantial vaccines franchise; representative of the global incumbents that constrain pricing and market access for emerging vaccine developers.
- GSK Vaccines: Vaccines division of GSK, a global leader across pediatric, travel, and adult vaccines; sets the competitive reference point for specialty vaccine players like Vivalis.
- Pfizer Vaccines: Major vaccine player post-COVID-19 portfolio expansion; broad incumbent whose scale and commercialization capability sets the bar for emerging vaccine biotechs.
Market position
Customer concentration
Vivalis financial estimates
Financial estimateRevenue estimate
Valuation estimate
Vivalis leadership team
Management profileNumber of profiles
Vivalis funding detail
Funding detailFunding overview
Funding rounds
Investors
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Vivalis M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Vivalis
What does Vivalis do?
Vivalis SA was a French biotechnology company operating in the pharmaceutical vaccines sector. The company merged with Intercell AG on May 28, 2013 to form Valneva SE, and its original website now redirects to the successor entity at www.valneva.com.
Is Vivalis a public or private company?
Vivalis is a private company. It is classified as unknown and is currently acquired.
When was Vivalis founded?
Vivalis was founded in 1999. It employs 101 to 250 people.
Where is Vivalis based?
Vivalis is headquartered in Saint-herblain, France, in the Europe region.
Who are Vivalis's main competitors?
Direct peers on record are Emergent BioSolutions, Bavarian Nordic and Novavax. Emerging players are BioNTech, Moderna and Dynavax Technologies. Broad incumbents are Sanofi Pasteur, Merck Vaccines (MSD), GSK Vaccines and Pfizer Vaccines.
Does Vivalis have an API?
No public API is recorded for Vivalis.
What industry is Vivalis in?
Vivalis's product category is Vaccines. Its primary akta.pro industry code is HLAIAEAJ, Vaccine Manufacturing & Fill-Finish. Its NAICS code is 325412 and its SIC code is 2834.